Psychedelics

Latest News

October 25th 2021

Dune and the Second Coming of Psychedelics in the United States

By H. Steven Moffic, MD

What does the movie Dune say about our society’s current relationship with psychedelics?

August 17th 2021

Developing a Novel Psychedelic: Salvinorin A

By Leah Kuntz

April 6th 2021

David Hellerstein, MD: Psychedelic Treatments for Psychiatric Disorders

By Angela A. Coombs, MD, Jennifer Sotsky, MD, MS

March 23rd 2021

Psychedelic Wellness

By Matt Stang

October 16th 2020

The New Frontier: Psychedelics as Treatment

By Leah Kuntz

CME Content

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

LIPSKIY/SHUTTERSTOCK.COM; WITHTHESEHANDS/SHUTTERSTOCK.COM

Revisiting the Hallucinogenic Potential of Ketamine

ByDavid S. Mathai, MD,Sanjay J. Mathew, MD,Eric A. Storch, PhD,Thomas R. Kosten, MD

June 26th 2018

An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.

Innovative Strategies for Addressing Substance Use Disorders: The Classic Hallucinogens

ByMichael P. Bogenschutz, MD

April 20th 2017

Here: a review of the scientific evidence relevant to the use of classic hallucinogens in the treatment of substance use disorders.

Psychedelics

Latest News

CME Content

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Revisiting the Hallucinogenic Potential of Ketamine

Innovative Strategies for Addressing Substance Use Disorders: The Classic Hallucinogens

Trending on Psychiatric Times

Transcranial Magnetic Stimulation in Sports Performance: Promise, Physiology, and Precaution

Semaglutide Potentially Protective Against Nephrotoxicity Caused by Lithium

NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia

FDA Accepts NDA for TRN-257 for Treatment of Narcolepsy and Idiopathic Hypersomnia

Postoperative Delirium in Older Patients: Signs, Symptoms, Solutions